Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Feasibility of targeted cascade genetic testing in the family members of BRCA1/2 gene pathogenic variant/likely pathogenic variant carriers.

Scientific reports - 3 Feb 2022

Lee Jeeyeon, Ham Ji Yeon, Park Ho Yong, Jung Jin Hyang, Kim Wan Wook, Kang Byeongju, Chae Yee Soo, Lee Soo Jung, Lee In Hee, Lee Nan Young

Abstract excerpt

The pathogenic variant (PV) or likely pathogenic variant (LPV) BRCA1/2 gene is strongly associated with hereditary breast or ovarian cancer. Therefore, it is important to screen blood relatives to establish preventive modalities and surveillance. This study evaluated the feasibility of targeted cascade genetic testing for family members of BRCA1/2 gene PV or LPV carriers. We screened 18 families for BRCA1/2 gene...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to BRCA1 Protein
Share to BRCA2 Protein

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Breast Neoplasms

Share to Feasibility Studies

Share to Genetic Carrier Screening

Share to Heredity

Share to Heterozygote

Share to Predictive Value of Tests

Source

Open in PubMed Open full text

Identifiers

PMID: 35115620
DOI: 10.1038/s41598-022-05931-3
PMCID: PMC8813990

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 9 closest

Feasibility of targeted cascade genetic testing in the family members of BRCA1/2 gene pathogenic variant/likely pathogenic variant carriers.PMID 35115620Read ↗

Only 32.3% of Breast Cancer Families with Pathogenic Variants in Cancer Genes Utilized Cascade Genetic TestingSemantic proximity Read ↗

High-risk pathogenic germline variants in blood relatives of BRCA1/2 negative probands.Semantic proximity Read ↗

A comparative study of molecular characteristics of pathogenic and uncertain significance variants of BRCA1/2 in Chinese breast cancer patients.Semantic proximity Read ↗

Prevalence of BRCA1 and BRCA2 pathogenic variants in 8627 unselected patients with breast cancer: stratification of age at diagnosis, family history and molecular subtype.Semantic proximity Read ↗

Factors affecting the implementation of cascade testing of patients with BRCA1 or BRCA2 pathogenic germline variants in Japan.Semantic proximity Read ↗

Cascade testing for hereditary cancer: comprehensive multigene panels identify unexpected actionable findings in relatives.Semantic proximity Read ↗

Uptake of cascade tests in relatives of patients undergoing cancer precision medicine in Japan.Semantic proximity Read ↗

Comprehensive genetics clinic for familial tumors: proposal for a suitable system in Japan.Semantic proximity Read ↗

Collaboration of breast cancer clinic and genetic counseling division for BRCA1 and BRCA2 mutation family in Japan.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.